Stockpile Bio is bouncing carelessly into the cell treatment field, and its most recent raising money to pull, moved to some degree by Bristol Myers Squibb, is shaking things up. The organization has pulled in $220 million in series B cash — one of the biggest single drags of 2022 — away the commitment to […]